© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Brain Cancer | Clinical
FDA Approves Naxitamab for Treatment of Relapsed/Refractory High-Risk Neuroblastoma
November 25, 2020
The FDA has granted approval to the naxitamab as treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease on prior treatment.
ReSPECT Study Shows Positive Results in Recurrent Glioblastoma
November 23, 2020
The investigational drug Rhenium NanoLiposome demonstrated efficacy in an interim analysis presented at the 2020 Society for Neuro-Oncology Annual Meeting for patients with recurrent glioblastoma.
Investigational DNA-Targeting Agent Shows Efficacy in MGMT-Unmethylated GBM
November 20, 2020
Patients with newly-diagnosed, recurrent, and first-line MGMT-unmethylated glioblastoma multiforme exhibited a promising median progression-free survival and median overall survival in two phase 2 trials of VAL-083 compared with historical data.
Clinical Investigation Into Antibody With Activity Against SSTR2 and CD3 Moves Forward
November 16, 2020
Positive preliminary data from the phase 1 DUET-1 study examining XmAb18087 in patients with neuroendocrine tumors demonstrated promising safety and efficacy findings.
A More Frequent Lanreotide Dose May Delay the Need for Other Therapies in NETs
November 12, 2020
Results of the CLARINET FORTE study indicate that a dosing strategy of lanreotide given every 14 days may be a viable and safe option when the standard administration of every 28 days is not acceptable.
FDA Accepts Investigational New Drug Application for NUV-422 as Treatment of High-Grade Gliomas
October 13, 2020
The FDA has accepted an investigational New Drug application for the investigational CDK2/4/6 inhibitor NUV-422 for the treatment of patients with high-grade gliomas.
Study Aims to Explore Treatment Modalities in Patients With Multiple Brain Metastases
September 25, 2020
In an interview with Targeted Oncology, David Roberge, MD, discussed the role of radiation treatment in patients with brain metastases and the clinical trial evaluating treatment approaches for patients with more than 5 brain metastases.
Limited Activity Shown With Durvalumab/Tremelimumab in Advanced NETs Subtypes
September 22, 2020
Results from the DUNE trial of durvalumab added to tremelimumab in patients with advanced neuroendocrine tumors of gastroenteropancreatic and lung origins showed limited activity, according to a presentation held during the 2020 European Society of Medical Oncology Virtual Congress.
Neuro-Oncologists Await Late-Phase Clinical Trial Exploration of Enzastaurin in Glioblastoma
September 17, 2020
Enzastaurin is on track to serve an unmet medical need in the treatment landscape of glioblastoma. Neuro-oncologists are waiting on the launch of an important clinical trial to further demonstrate the efficacy of the drug.
FDA Grants Orphan Drug Designation to RNL in Recurrent Glioblastoma
September 02, 2020
The FDA has granted an Orphan Drug designation to rhenium nanoLiposomes for the treatment of patients with recurrent glioblastoma.